

Poster presentation

Open Access

Thrombopenia and/or splenomegaly in HIV/HCV co-infected patients with mild liver fibrosis alerts for the risk of portal hepatopathy

E Vispo*, I Maida, P Barreiro, V Moreno and V Soriano

Address: Hospital Carlos III, Madrid, Spain

* Corresponding author

from Ninth International Congress on Drug Therapy in HIV Infection
Glasgow, UK. 9–13 November 2008

Published: 10 November 2008

Journal of the International AIDS Society 2008, **11**(Suppl 1):P286 doi:10.1186/1758-2652-11-S1-P286

This abstract is available from: <http://www.jiasociety.org/content/11/S1/P286>

© 2008 Vispo et al; licensee BioMed Central Ltd.

Background

Non-cirrhotic portal hypertension has recently emerged as a new entity in HIV-infected patients. Histological findings often reveal different hepatic portal perivascular abnormalities. In most cases it was related to previous didanosine exposure. Although its recognition could be more difficult, this drug-induced vascular damage in the liver might also appear in HIV/HCV co-infected patients.

Clinical cases

Three HIV individuals with chronic hepatitis C presented with complicated portal hypertension as oesophageal variceal bleeding. Liver fibrosis measured by transient elastometry did not reveal advanced liver fibrosis. Liver function tests were completely normal. All subjects presented previous clinical signs of portal hypertension, thrombopenia and splenomegaly, lasting on average 4 and 2 years, respectively. They had been exposed to didanosine for long periods in the past. (Table 1.)

Discussion

Primary hepatic vascular damage induced by didanosine might result in non-cirrhotic portal hypertension. This condition may appear in HIV patients without any known cause of liver disease, as well as superimposed to other hepatic illnesses, as chronic hepatitis C. The recognition of clinical classical signs of portal hypertension (e.g. thrombopenia, splenomegaly) in the absence of a significant liver fibrosis or synthetic function compromise may alert to the possibility of this condition.

Table 1:

	Case 1	Case 2	Case 3
Age (years)	41	49	42
Gender	Male	Female	Male
Race	Caucasian	Caucasian	Caucasian
Risk group	IDU	IDU	IDU
On HAART	Yes	Yes	Yes
Prior didanosine exposure (months)	64	30	44
CD4 count (cells/mm ³)	351	168	324
Plasma HIV-RNA (copies/ml)	<50	<50	<50
Platelet count/ul	78,000	57,000	81,000
Liver fibrosis stage (Metavir, stiffness KPa)	F2 (9)	F3 (11.5)	F4 (15)
Splenomegaly	Yes	Yes	Yes

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

